ProShare Advisors’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $991K | Sell |
68,562
-21,262
| -24% | -$305K | ﹤0.01% | 793 |
|
|
2025
Q4 | $1.28M | Buy |
89,824
+31,231
| +53% | +$307K | ﹤0.01% | 760 |
|
|
2025
Q3 | $462K | Sell |
58,593
-10,004
| -15% | -$71.2K | ﹤0.01% | 1160 |
|
|
2025
Q2 | $393K | Sell |
68,597
-8,783
| -11% | -$56.7K | ﹤0.01% | 1260 |
|
|
2025
Q1 | $631K | Sell |
77,380
-19,407
| -20% | -$180K | ﹤0.01% | 982 |
|
|
2024
Q4 | $912K | Buy |
96,787
+23,815
| +33% | +$248K | ﹤0.01% | 949 |
|
|
2024
Q3 | $779K | Buy |
72,972
+15,811
| +28% | +$172K | ﹤0.01% | 891 |
|
|
2024
Q2 | $567K | Sell |
57,161
-15,684
| -22% | -$161K | ﹤0.01% | 910 |
|
|
2024
Q1 | $858K | Buy |
72,845
+7,068
| +11% | +$90.4K | ﹤0.01% | 835 |
|
|
2023
Q4 | $933K | Buy |
65,777
+10,576
| +19% | +$120K | ﹤0.01% | 770 |
|
|
2023
Q3 | $671K | Buy |
55,201
+317
| +0.6% | +$4.09K | ﹤0.01% | 806 |
|
|
2023
Q2 | $689K | Buy |
54,884
+2,949
| +6% | +$35K | ﹤0.01% | 819 |
|
|
2023
Q1 | $576K | Sell |
51,935
-6,787
| -12% | -$83.7K | ﹤0.01% | 859 |
|
|
2022
Q4 | $717K | Buy |
58,722
+4,725
| +9% | +$53.2K | ﹤0.01% | 828 |
|
|
2022
Q3 | $563K | Buy |
53,997
+1,211
| +2% | +$13.5K | ﹤0.01% | 869 |
|
|
2022
Q2 | $566K | Sell |
52,786
-25,507
| -33% | -$210K | ﹤0.01% | 896 |
|
|
2022
Q1 | $741K | Sell |
78,293
-18,335
| -19% | -$172K | ﹤0.01% | 1052 |
|
|
2021
Q4 | $1.12M | Buy |
96,628
+5,985
| +7% | +$66.7K | ﹤0.01% | 965 |
|
|
2021
Q3 | $866K | Sell |
90,643
-25,387
| -22% | -$260K | ﹤0.01% | 953 |
|
|
2021
Q2 | $1.12M | Buy |
116,030
+11,184
| +11% | +$109K | ﹤0.01% | 973 |
|
|
2021
Q1 | $1.04M | Buy |
104,846
+7,659
| +8% | +$119K | ﹤0.01% | 962 |
|
|
2020
Q4 | $2.24M | Buy |
97,187
+24,326
| +33% | +$497K | 0.01% | 609 |
|
|
2020
Q3 | $1.03M | Sell |
72,861
-2,868
| -4% | -$41.8K | ﹤0.01% | 715 |
|
|
2020
Q2 | $1.14M | Buy |
75,729
+25,671
| +51% | +$313K | 0.01% | 673 |
|
|
2020
Q1 | $463K | Sell |
50,058
-39,730
| -44% | -$378K | ﹤0.01% | 745 |
|
|
2019
Q4 | $875K | Sell |
89,788
-8,282
| -8% | -$75.8K | ﹤0.01% | 839 |
|
|
2019
Q3 | $787K | Buy |
98,070
+5,861
| +6% | +$63.6K | ﹤0.01% | 834 |
|
|
2019
Q2 | $1.15M | Sell |
92,209
-4,370
| -5% | -$55.5K | 0.01% | 717 |
|
|
2019
Q1 | $1.31M | Buy |
96,579
+12,520
| +15% | +$153K | 0.01% | 695 |
|
|
2018
Q4 | $805K | Sell |
84,059
-16,230
| -16% | -$178K | 0.01% | 773 |
|
|
2018
Q3 | $1.21M | Sell |
100,289
-3,853
| -4% | -$53.9K | 0.01% | 745 |
|
|
2018
Q2 | $1.63M | Sell |
104,142
-5,513
| -5% | -$83.3K | 0.01% | 664 |
|
|
2018
Q1 | $1.65M | Sell |
109,655
-4,710
| -4% | -$71.7K | 0.01% | 660 |
|
|
2017
Q4 | $1.65M | Buy |
114,365
+10,315
| +10% | +$142K | 0.01% | 664 |
|
|
2017
Q3 | $1.57M | Buy |
104,050
+18,009
| +21% | +$238K | 0.01% | 620 |
|
|
2017
Q2 | $866K | Sell |
86,041
-6,325
| -7% | -$50.9K | 0.01% | 771 |
|
|
2017
Q1 | $659K | Sell |
92,366
-24,545
| -21% | -$155K | 0.01% | 902 |
|
|
2016
Q4 | $581K | Buy |
116,911
+13,193
| +13% | +$91.3K | 0.01% | 1008 |
|
|
2016
Q3 | $768K | Sell |
103,718
-6,436
| -6% | -$43.5K | 0.01% | 764 |
|
|
2016
Q2 | $601K | Buy |
110,154
+3,291
| +3% | +$23K | 0.01% | 888 |
|
|
2016
Q1 | $903K | Sell |
106,863
-10,455
| -9% | -$74K | 0.01% | 734 |
|
|
2015
Q4 | $1.14M | Buy |
117,318
+15,789
| +16% | +$142K | 0.01% | 685 |
|
|
2015
Q3 | $1.42M | Buy |
101,529
+12,320
| +14% | +$193K | 0.02% | 575 |
|
|
2015
Q2 | $1.26M | Buy |
89,209
+12,223
| +16% | +$147K | 0.02% | 663 |
|
|
2015
Q1 | $838K | Buy |
76,986
+15,280
| +25% | +$135K | 0.01% | 935 |
|
|
2014
Q4 | $513K | Buy |
+61,706
| New | +$424K | 0.01% | 1186 |
|
|
2014
Q2 | – | Sell |
-30,782
| Closed | -$64K | – | 2501 |
|
|
2014
Q1 | $64K | Buy |
+30,782
| New | +$77K | ﹤0.01% | 2712 |
|
|
2013
Q4 | – | Sell |
-36,636
| Closed | -$85K | – | 1525 |
|
|
2013
Q3 | $85K | Buy |
36,636
+7,555
| +26% | +$19K | ﹤0.01% | 2452 |
|
|
2013
Q2 | $68K | Buy |
+29,081
| New | +$89.4K | ﹤0.01% | 2326 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
ProShare Advisors's FOLD Position: Q1 2026 in Review
ProShare Advisors reduced its Amicus Therapeutics (FOLD) stake by 24% in Q1 2026, selling an estimated $305K and leaving 68,562 shares worth $991K. The position accounts for ﹤0.01% of the portfolio, ranked #793.
ProShare Advisors first reported a position in FOLD in Q2 2013 and has held it in 49 quarters since. The position peaked at $2.24M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- ProShare Advisors held 68,562 shares of Amicus Therapeutics worth $991K as of Q1 2026.
- ProShare Advisors sold 21,262 Amicus Therapeutics shares in Q1 2026, an estimated $305K.
- Amicus Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #793 holding.
- ProShare Advisors first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 49 quarters since.
- ProShare Advisors's Amicus Therapeutics position peaked at $2.24M in Q4 2020.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.